CorteseIReichDSNathA.Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol2021; 17(1): 37–51.
2.
RyersonLZFoleyJChangI, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology2019; 93(15): e1452.
3.
WenningWHaghikiaALaubenbergerJ, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. New Engl J Medicine2009; 361(11): 1075–1080.
4.
CorteseIMuranskiPEnose-AkahataY, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. New Engl J Med2019; 380(17): 1597–1605.
5.
BoumazaXBonneauBRoos-WeilD, et al. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann Neurol2022, https://doi.org/10.1002/ana.26512
6.
DalakasMC.Neurological complications of immune checkpoint inhibitors: What happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord2018; 11: 1756286418799864.
7.
PawlitzkiMSchneider-HohendorfTRolfesL, et al. Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue. Neurol Neuroimmunol Neuroinflamm2019; 6(6): e627.
